NZ595941A - Treatment of neurodegeneration and neuroinflammation - Google Patents
Treatment of neurodegeneration and neuroinflammationInfo
- Publication number
- NZ595941A NZ595941A NZ595941A NZ59594110A NZ595941A NZ 595941 A NZ595941 A NZ 595941A NZ 595941 A NZ595941 A NZ 595941A NZ 59594110 A NZ59594110 A NZ 59594110A NZ 595941 A NZ595941 A NZ 595941A
- Authority
- NZ
- New Zealand
- Prior art keywords
- medicament
- treatment
- dosing period
- dose
- formulated
- Prior art date
Links
- 208000036110 Neuroinflammatory disease Diseases 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 230000003959 neuroinflammation Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 5
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 3
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ617130A NZ617130A (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17379709P | 2009-04-29 | 2009-04-29 | |
| US17527009P | 2009-05-04 | 2009-05-04 | |
| PCT/US2010/001282 WO2010126605A1 (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595941A true NZ595941A (en) | 2014-02-28 |
Family
ID=43032484
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595941A NZ595941A (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
| NZ617130A NZ617130A (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ617130A NZ617130A (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120165404A1 (enExample) |
| EP (3) | EP3466420A1 (enExample) |
| JP (3) | JP2012525385A (enExample) |
| CN (2) | CN102427727A (enExample) |
| AU (1) | AU2010242064A1 (enExample) |
| CA (1) | CA2760133A1 (enExample) |
| HK (1) | HK1255133A1 (enExample) |
| NZ (2) | NZ595941A (enExample) |
| WO (1) | WO2010126605A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| SI2801354T1 (sl) * | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| PT2139467T (pt) * | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| KR101699912B1 (ko) | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
| JPWO2010098429A1 (ja) | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
| US20140142095A1 (en) * | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| EP2713724A4 (en) * | 2011-05-26 | 2015-03-11 | Biogen Idec Inc | METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT |
| JP6385273B6 (ja) | 2011-06-08 | 2023-12-15 | バイオジェン・エムエイ・インコーポレイテッド | 高純度結晶性ジメチルフマラートの調製方法 |
| HK1202885A1 (en) * | 2011-12-16 | 2015-10-09 | Biogen Ma Inc. | Silicon-containing fumaric acid esters |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN113244185A (zh) * | 2012-02-07 | 2021-08-13 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| JP2013220090A (ja) * | 2012-04-19 | 2013-10-28 | Tohoku Univ | 眼疾患治療に使用する薬剤スクリーニング方法 |
| JP2015527372A (ja) * | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| JP6506174B2 (ja) * | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| CN103173544B (zh) * | 2013-03-05 | 2015-01-28 | 浙江大学 | Leber病之线粒体T3866C检测试剂盒及应用 |
| CN105452213B (zh) | 2013-03-14 | 2017-09-22 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| US20160310457A1 (en) * | 2013-12-12 | 2016-10-27 | Almirall, S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
| CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| AU2015381240A1 (en) | 2015-02-08 | 2017-07-06 | Alkermes Pharma Ireland Limited | Monomethylfumarate prodrug compositions |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| WO2017056107A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Ltd | Pharmaceutical compositions of dimethyl fumarate |
| GR1009149B (el) * | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| MA49448A (fr) | 2017-06-23 | 2020-04-29 | Almirall Sa | Compositions pharmaceutiques contenant du fumarate de diméthyle |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| CN108904779B (zh) * | 2018-09-29 | 2019-12-03 | 南华大学 | 曲普瑞林的新应用 |
| CN109364058A (zh) * | 2018-12-05 | 2019-02-22 | 中南大学湘雅医院 | 富马酸酯及其可药用盐在制备治疗铁死亡相关疾病的药物中的应用 |
| US20220087942A1 (en) | 2019-05-31 | 2022-03-24 | Curacle Co., Ltd. | Enteric tablet containing dimethyl fumarate |
| WO2021092536A1 (en) * | 2019-11-08 | 2021-05-14 | The Children's Hospital Of Philadelphia | Compositions and methods for treating macrophage activation syndrome |
| CN113117081B (zh) * | 2019-12-30 | 2024-12-24 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2022203432A1 (ko) | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| CN115487297A (zh) * | 2021-06-17 | 2022-12-20 | 清华大学 | 治疗神经元蜡样质脂褐质沉积症的方法和药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| JP2004041208A (ja) * | 2002-07-15 | 2004-02-12 | Sankyo Co Ltd | インスリン抵抗性改善効果の評価方法 |
| SI2801354T1 (sl) | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007005879A2 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20100144651A1 (en) | 2005-07-07 | 2010-06-10 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| WO2007006307A2 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080299196A1 (en) * | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| WO2008039876A1 (en) * | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| PT2139467T (pt) * | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| DK2653873T3 (da) * | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| KR101699912B1 (ko) * | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
-
2010
- 2010-04-29 EP EP18206136.6A patent/EP3466420A1/en not_active Withdrawn
- 2010-04-29 WO PCT/US2010/001282 patent/WO2010126605A1/en not_active Ceased
- 2010-04-29 JP JP2012508485A patent/JP2012525385A/ja not_active Withdrawn
- 2010-04-29 EP EP17202547.0A patent/EP3318249A1/en not_active Withdrawn
- 2010-04-29 AU AU2010242064A patent/AU2010242064A1/en not_active Abandoned
- 2010-04-29 EP EP10770066A patent/EP2424357A4/en not_active Withdrawn
- 2010-04-29 CN CN2010800215056A patent/CN102427727A/zh active Pending
- 2010-04-29 CA CA2760133A patent/CA2760133A1/en not_active Abandoned
- 2010-04-29 NZ NZ595941A patent/NZ595941A/en not_active IP Right Cessation
- 2010-04-29 NZ NZ617130A patent/NZ617130A/en not_active IP Right Cessation
- 2010-04-29 US US13/266,997 patent/US20120165404A1/en not_active Abandoned
- 2010-04-29 CN CN201410648177.2A patent/CN104523673A/zh active Pending
-
2014
- 2014-11-13 US US14/540,136 patent/US20150132747A1/en not_active Abandoned
- 2014-11-27 JP JP2014239565A patent/JP2015044855A/ja active Pending
-
2016
- 2016-04-28 JP JP2016090250A patent/JP2016175926A/ja active Pending
-
2018
- 2018-11-07 HK HK18114182.9A patent/HK1255133A1/en unknown
- 2018-11-29 US US16/204,076 patent/US20190195860A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102427727A (zh) | 2012-04-25 |
| JP2015044855A (ja) | 2015-03-12 |
| JP2012525385A (ja) | 2012-10-22 |
| AU2010242064A1 (en) | 2011-11-17 |
| US20190195860A1 (en) | 2019-06-27 |
| WO2010126605A1 (en) | 2010-11-04 |
| AU2010242064A2 (en) | 2013-10-10 |
| NZ617130A (en) | 2015-06-26 |
| JP2016175926A (ja) | 2016-10-06 |
| CN104523673A (zh) | 2015-04-22 |
| HK1255133A1 (en) | 2019-08-09 |
| EP3466420A1 (en) | 2019-04-10 |
| EP3318249A1 (en) | 2018-05-09 |
| EP2424357A4 (en) | 2012-10-10 |
| EP2424357A1 (en) | 2012-03-07 |
| US20150132747A1 (en) | 2015-05-14 |
| CA2760133A1 (en) | 2010-11-04 |
| US20120165404A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL149147A0 (en) | Use of oxcarbazepine for the manufacture of oral dosage form medicament | |
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| EP2043637B8 (en) | Methods and medicaments for administration of ibuprofen | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| NZ736048A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| EP4327888A3 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013231087A5 (enExample) | ||
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| MX2011007779A (es) | Formulaciones galenicas de compuestos organicos. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| MX2010008235A (es) | Nueva dosificacion y formulacion. | |
| NZ576424A (en) | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| TW200640497A (en) | Pharmaceutical formulations and methods of use | |
| JP2013516493A5 (enExample) | ||
| NZ592049A (en) | Compositions and methods for the treatment of bowel diseases with granulated mesalamine | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| WO2008106689A3 (en) | Breakthrough pain management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 APR 2017 BY CULLENS Effective date: 20140623 |
|
| LAPS | Patent lapsed |